Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol

Carcinogenesis

Volumn 34, Issue 4, 2013, Pages 858-863

  Husain, Kazim ^a   Centeno, Barbara A ^a   Chen, Dung Tsa ^a   Fulp, William J ^a   Perez, Marta ^a   Zhang lee, Guo ^a   Luetteke, Noreen ^a   Hingorani, Sunil R ^b   Sebti, Said M ^a   Malafa, Mokenge P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; BIOLOGICAL MARKER; CASPASE 3; DELTA TOCOTRIENOL; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; GENOTYPING TECHNIQUE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CASPASE 3; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENOTYPE; HOMEODOMAIN PROTEINS; MICE; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR RELA; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 84875923384     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt002     Document Type: Article

References (34)

1. Hong,S.M. et al. (2012) Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin. Cancer Res., 18, 4303-4312.
2. Kanda,M. et al. (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology, 142, 730-733.e9.
3. Hruban,R.H. et al. (2010) Update on familial pancreatic cancer. Adv. Surg., 44, 293-311.
4. Skoulidis,F. et al. (2010) Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell, 18, 499-509.
5. Al-Sukhni,W. et al. (2012) Identification of germline genomic copy number variation in familial pancreatic cancer. Hum. Genet., 131, 1481-1494.
6. Matthaei,H. et al. (2011) Cystic precursors to invasive pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol., 8, 141-150.
7. Wu,J. et al. (2011) Wholeexome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc. Natl. Acad. Sci. U.S.A., 108, 21188-21193.
8. Canto,M.I. et al. (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology, 142, 796-804; quiz e14-15.
9. Collins,M.A. et al. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest., 122, 639-653.
10. Ying,H. et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149, 656-670.
11. Kim,S.T. et al. (2011) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol. Cancer Ther., 10, 1993-1999.
12. Lee,J. et al. (2007) Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer, 109, 1561-1569.
13. Grana,T.M. et al. (2002) Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res., 62, 4142-4150.
14. Kullmann,F. et al. (2011) KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology, 81, 3-8.
15. Hingorani,S.R. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-450.
16. Olive,K.P. et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324, 1457-1461.
17. Provenzano,P.P. et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 21, 418-429.
18. Hertel,L.W. et al. (1990) Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res., 50, 4417-4422.
19. Aggarwal,B.B. et al. (2010) Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem. Pharmacol., 80, 1613-1631.
20. Ji,X. et al. (2012) Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int. J. Cancer, 131, 2668-2677.
21. Ling,M.T. et al. (2012) Tocotrienol as a potential anticancer agent. Carcinogenesis, 33, 233-239.
22. Husain,K. et al. (2011) Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol. Cancer Ther., 10, 2363-2372.
23. Husain,K. et al. (2009) Vitamin E delta-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology, 83, 157-163.
24. Hussein,D. et al. (2009) d-δ-Tocotrienol-mediated suppression of the pro-liferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells. Pancreas, 38, e124-e136.
25. Song,B.L. et al. (2006) Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta-and gamma-tocotrienols. J. Biol. Chem., 281, 25054-25061.
26. Shin-Kang,S. et al. (2011) Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med., 51, 1164-1174.
27. Funahashi,H. et al. (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res., 67, 7068-7071.
28. Hingorani,S.R. et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7, 469-483.
29. Gysin,S. et al. (2005) Pharmacologic inhibition of RAF->MEK->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res., 65, 4870-4880.
30. Ahn,K.S. et al. (2007) Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem., 282, 809-820.
31. Kannappan,R. et al. (2010) Gamma-Tocotrienol but not gamma-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem., 285, 33520-33528.
32. Samant,G.V. et al. (2010) Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif., 43, 77-83.
33. Mohammed,A. et al. (2010) The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev. Res. (Phila)., 3, 1417-1426.
34. Mohammed,A. et al. (2012) Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int. J. Cancer, 131, 1951-1962.